Attacking Bladder Cancer for a Better Tomorrow | 1 Disclaimer and Forward -Looking Statements We caution you that this presentation contains forward -looking statements about us and our industry. All statements other than s tatements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, rese arch and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical ...

Q1 FY26 Financial Performance - Net sales increased by 1% to $154.4 million, compared to $153.5 million in Q1 FY25 [12] - Gross margin improved by 140 basis points to 56.2% [12] - Operating income decreased by 7% to $23.3 million [12] - Net income decreased by 8% to $17.5 million [12] - Diluted EPS decreased by 8% to $1.28 [12] Segment Performance - Americas segment sales increased by 4%, representing 47% of global net sales [14] - EIMEA segment sales increased by 2%, representing 38% of global net sales [20] - Asia-Pacific segment sales increased by 10%, representing 15% of global net sales [22] Growth and Strategy - The company is targeting long-term maintenance product sales growth with a CAGR target in the mid-to-high single digits [31] - The company is focused on four strategic battles: geographic expansion, premiumization, WD-40 Specialist growth, and digital commerce [34] FY26 Guidance - The company reaffirmed FY26 sales growth guidance between 5% and 9%, leading to net sales between $630 million and $655 million [53]

NYSE: GBX 1Q26 Earnings Slides & Supplemental Information InvestorRelations@gbrx.com www.gbrx.com Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements, including statements that are not purely statements of historical fact. The Greenbrier Companies, Inc. (the "Company," "we," "us" or "our") uses words, and variations of words, such as "backlog," "believe," "capacity," "commit," "continue," "drive," "estimate," "expect," "focus," "future," "gr ...

Earnings Call: Q1 - FY26 January 8, 2026 $0.03 Diluted EPS $18.4M Revenue 19% Adj. EBITDA Margin -3% Revenue Decline Current period Prior Year Comparison (1Q25) $0.13 Adj. Diluted EPS $18.9M Revenue $0.01 Diluted EPS 24% Adj. EBITDA Margin +31% $0.17 Revenue Growth Adj. Diluted EPS Trailing Twelve Months (TTM) Highlights ($3.20) Diluted EPS (1) $78.7M Revenue 27% Adj. EBITDA Margin +6% Revenue Growth Current period Prior Year Comparison (1Q25) $0.98 Adj. Diluted EPS $74.4M Revenue $0.40 Diluted EPS 29% Adj. ...

Phase 2 COACH Trial Topline Week 52 Data January 8, 2026 Treatment with TransCon CNP and TransCon hGH combination therapy is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding TransCon hGH's ability to complement TransCon CNP's ho ...

CORAL-1 Clinical Data Update - Krystal Biotech's KB407 is a gene therapy for cystic fibrosis (CF) and has the potential to become a leadership opportunity in the treatment of CF[9] - The company plans to initiate the CORAL-3 study in the first half of 2026 to evaluate the safety and efficacy of repeat KB407 administration, which could support registration of KB407[4, 93] - The company estimates a $2 billion+ market opportunity in modulator-ineligible or refractory CF patients[12] KB407 Phase 1 CORAL-1 Highest Dose Cohort Results - In patient 03-01 with CFTR genotype 2184delA/W1282X, 42.1% of conducting airway cells expressed CFTR[55] - In patient 03-02 with CFTR genotype R553X/M1V, 29.4% of conducting airway cells expressed CFTR[68] - In patient 03-03 with CFTR genotype C1210-12T/1408A>G, 36.5% of conducting airway cells were viral marker positive[76] - In patient 03-04 with CFTR genotype R334W/R1162X, 33.8% of conducting airway cells were viral marker positive[79] - In patient 03-05 with CFTR genotype F508del/F508del, 36.8% of conducting airway cells were viral marker positive[81] - In patient 03-06 with CFTR genotype F508del/F508del, 31.4% of conducting airway cells were viral marker positive[83]

RESPONSIBLE CARE® OUR COMMITMENT TO SUSTAINABILITY Refer to the Appendix for additional notices of caution regarding forward looking information. 2 TSX: CHE.UN 2026 Guidance 2026 Guidance: 2026 GUIDANCE Chemtrade Logistics Income Fund (TSX: CHE.UN) January 8, 2026 CAUTION REGARDING FORWARD- LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking statements within the meaning of certain securities laws, including the Securities Act (Ontario). Forward-looking statements ...

2026 PriceSmart, Inc. Overview Presentation Issued: January 2026 NASDAQ : PSMT 1 ForwardLookingStatements This presentation may contain forward-looking statements concerning PriceSmart, Inc.'s ("PriceSmart", the "Company" or "we") anticipated future revenues and earnings, adequacy of future cash flows, omni-channel initiatives, proposed warehouse club openings, the Company's performance relative to competitors and related matters. These forward-looking statements include, but are not limited to, statements ...

Financial Performance & Growth - Since Q1 2023, NewtekOne's book value/share has increased by 45% from $8.06 to $11.72[14] - Tangible common book value (TBV)/share has increased by 62% from $6.92 to $11.22 since Q1 2023[14] - NewtekOne has distributed $2.05 of common dividends/share over the eleven quarters since transitioning to a financial holding company[14] - The company's operating efficiency ratio has improved from over 70% in 2023 to 56.3% as of September 30, 2025[44] - Hypothetical $300 million loan pool generates $22.7 million of annual net interest income[84] Lending & Securitization - Approximately $850 million of originations across 180 loans in C&I loans held for sale since 2018[75] - The ALP securitization completed in April 2025 generates 570 bps of spread income after FV mark on securitization not including 100 bps of servicing income[75] - The advance rate for the 2026-1 securitization is 86%, with an ALP Loan Pool of $340 million[76] Newtek Advantage Platform - Newtek Bank has grown to $1.5 billion in assets (7x over three years) since acquisition[44] - The platform generates approximately 600 new referrals per day as a client acquisition tool[44] - In 2025, NewtekOne originated over $1.4 billion in loans[45]

Financial Performance & Outlook - Q1 Net Earnings reached $1773 million[15], while Adjusted Earnings were $2062 million[15] - Q1 Core EBITDA stood at $3169 million[15], with a Core EBITDA Margin of 149%[15] - The company aims to exit FY 2026 with an annualized run-rate EBITDA benefit of $150 million from TAG initiatives[14, 21] - Precast business is expected to contribute approximately $165 million to $175 million to Construction Solutions Group Adjusted EBITDA in fiscal 2026[34] Strategic Initiatives - The company launched new Transform, Advance, Grow ("TAG") initiatives with commercial opportunities in focus[14, 19] - The company rebranded Emerging Businesses Group to Construction Solutions Group to better reflect business composition and strategic role of segment[14, 28] - The company completed acquisitions of Concrete Pipe & Precast ("CP&P") and Foley Products Company ("Foley")[2, 34] Market Dynamics - Construction Solutions Group net sales were up 170% year-over-year, while adjusted EBITDA increased by 747%[52, 65] - Europe Steel Group shipments increased by 157% on a year-over-year basis[52, 72] - The company anticipates reducing net debt to adjusted EBITDA to below 2x within 18 months[14, 46]